INHIBRX BIOSCIENCES, INC. Increase (Decrease) in Accrued Liabilities
INHIBRX BIOSCIENCES, INC. (INBX) reported Increase (Decrease) in Accrued Liabilities of -$9.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $431.00K.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$10.19M, a 453.22% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$1.43M.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$1.51M, a 125.12% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2025 was -$4.36M, a 112.15% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $35.88M, a 37.64% increase from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $26.07M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $431.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$9.76M 10-Q · filed 2026-08-13 | -$11.19M derived: sum of 3 quarters · filed 2026-08-13 | -$12.71M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$10.19M 10-Q · filed 2026-05-14 | -$11.62M derived: sum of 2 quarters · filed 2026-05-14 | -$13.14M derived: sum of 3 quarters · filed 2026-05-14 | -$17.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$2.95M derived: sum of 2 quarters · filed 2026-03-19 | -$7.25M derived: sum of 3 quarters · filed 2026-08-13 | -$4.36M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$5.81M derived: sum of 2 quarters · filed 2026-08-13 | -$2.93M 10-Q · filed 2025-11-14 | -$2.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$4.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.41M 10-Q · filed 2026-08-13 | -$1.41M derived: sum of 3 quarters · filed 2026-08-13 | $4.62M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.88M 10-Q · filed 2026-05-14 | $2.88M derived: sum of 2 quarters · filed 2026-05-14 | $8.91M derived: sum of 3 quarters · filed 2026-05-14 | $30.73M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $6.03M derived: sum of 2 quarters · filed 2026-03-19 | $27.85M derived: sum of 3 quarters · filed 2026-03-19 | $35.88M 10-K · filed 2026-03-19 |
| 2024-09-30 | $6.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $27.85M derived: sum of 2 quarters · filed 2025-11-14 | $35.88M 10-Q · filed 2025-11-14 | $53.28M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $21.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $29.85M 10-Q · filed 2025-08-13 | $47.25M derived: sum of 3 quarters · filed 2025-08-13 | $53.60M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $8.03M 10-Q · filed 2025-05-14 | $25.43M derived: sum of 2 quarters · filed 2025-05-14 | $31.78M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $17.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $23.74M derived: sum of 2 quarters · filed 2025-03-17 | $26.07M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $6.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $8.68M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $2.33M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |